SCHEMBL24549029

SCHEMBL24549029

CC(C)(C)OC(=O)n1ccc2c(F)cc(Br)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.40
BUB1 O43683 1/20 0.37
ACLY P53396 1/20 0.36
HTR6 P50406 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
AAK1 Q2M2I8 2/20 0.34
BCHE P06276 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
PIK3CA P42336 3/20 0.33
PIK3CD O00329 2/20 0.33
ABL1 P00519 2/20 0.33
EGFR P00533 2/20 0.33
HCK P08631 2/20 0.33
SRC P12931 2/20 0.33
KDR P35968 2/20 0.33
PIK3CB P42338 2/20 0.33
MTOR P42345 2/20 0.33
PIK3CG P48736 2/20 0.33
EPHB4 P54760 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29506984 1.00 USP30 (0.40) USP30BUB1ACLYHTR6L3MBTL1
SCHEMBL26683889 0.85 BUB1 (0.38) USP30BUB1HTR6L3MBTL1AAK1
SCHEMBL29507062 0.84 HSP90AA1 (0.39) USP30BUB1HTR6L3MBTL1AAK1
SCHEMBL24539514 0.84 HSP90AA1 (0.39) USP30BUB1HTR6L3MBTL1AAK1
SCHEMBL25338441 0.83 BUB1 (0.36) USP30BUB1HTR6L3MBTL1BCHE
SCHEMBL30620308 0.82 L3MBTL1 (0.43) USP30BUB1HTR6L3MBTL1BCHE
SCHEMBL3339983 0.81 PIK3CA (0.38) USP30BUB1ACLYHTR6L3MBTL1
SCHEMBL29331361 0.81 USP30 (0.42) USP30HTR6L3MBTL1AAK1BCHE
SCHEMBL25337812 0.81 SMN1; SMN2 (0.38) USP30BUB1HTR6L3MBTL1AAK1
SCHEMBL17113145 0.81 KMT2A (0.39) USP30BUB1HTR6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-02-15 US disclosed
CN-117321048-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-29 CN disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
EP-4221756-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2023-08-09 EP disclosed
CN-116249554-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2023-06-09 CN disclosed
WO-2022133098-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER RARA, RARG, RARB USP30 3710/4885BUB1 2935/4885ACLY 278/4885
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 USP30 2353/4885BUB1 1236/4885ACLY 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.